SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J. Peluso, Bryan Greenhouse, Keirstinne Turcios et al.|Science Advances|2021Cited by 150
Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detectionSusanna K. Elledge, James A. Wells, Xin Zhou et al.|Nature Biotechnology|2021Cited by 142
Extending chemical perturbations of the ubiquitin fitness landscape in a classroom setting reveals new constraints on sequence toleranceDavid Mavor, Douglas R. Wassarman, Kyle A. Barlow et al.|Biology Open|2018Cited by 29